Nature Communications (Oct 2018)
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
- Xiao Xiao,
- Jiankai Liang,
- Chunlong Huang,
- Kai Li,
- Fan Xing,
- Wenbo Zhu,
- Ziqing Lin,
- Wencang Xu,
- Guangen Wu,
- Jifu Zhang,
- Xi Lin,
- Yaqian Tan,
- Jing Cai,
- Jun Hu,
- Xueqin Chen,
- Youwei Huang,
- Zixi Qin,
- Pengxin Qiu,
- Xingwen Su,
- Lijun Chen,
- Yuan Lin,
- Haipeng Zhang,
- Guangmei Yan
Affiliations
- Xiao Xiao
- Institute of Clinical Medicine, The First Affiliated Hospital, University of South China
- Jiankai Liang
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Chunlong Huang
- Department of Hepatobiliary Surgery, The First Affiliated Hospital, Sun Yat-sen University
- Kai Li
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital of Sun Yat-sen University
- Fan Xing
- School of Medicine, Sun Yat-sen University
- Wenbo Zhu
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Ziqing Lin
- Guangzhou Virotech Pharmaceutical Co., Ltd
- Wencang Xu
- Guangzhou Virotech Pharmaceutical Co., Ltd
- Guangen Wu
- Guangzhou Virotech Pharmaceutical Co., Ltd
- Jifu Zhang
- Guangzhou Virotech Pharmaceutical Co., Ltd
- Xi Lin
- Department of Pharmacology, School of Medicine, Jinan University
- Yaqian Tan
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Jing Cai
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Jun Hu
- Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University
- Xueqin Chen
- Department of Pharmacology, School of Medicine, Jinan University
- Youwei Huang
- Department of Pharmacology, School of Medicine, Jinan University
- Zixi Qin
- Department of Pharmacology, School of Medicine, Jinan University
- Pengxin Qiu
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Xingwen Su
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Lijun Chen
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Yuan Lin
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- Haipeng Zhang
- Department of Pharmacology, School of Medicine, Jinan University
- Guangmei Yan
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University
- DOI
- https://doi.org/10.1038/s41467-018-06771-4
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Oncolytic virotherapy is a promising strategy for cancer treatment. In this study, the authors demonstrate that DNA-dependent protein kinase (DNA-PK) inhibition sensitizes cancer cells to M1 virus and improves therapeutic effects in refractory cancer models in vivo and in patient tumour samples.
